Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphorus-32 colloid (chromic phosphate P 32) is a radiotherapeutic agent used primarily for intracavitary administration to treat malignant effusions associated with advanced cancers, as well as cystic brain tumors such as craniopharyngioma and astrocytoma. It consists of the radioactive isotope phosphorus P‑32 in a colloidal suspension, which emits beta particles (β-) that induce localized cytotoxicity by damaging cellular DNA and generating free radicals. The limited tissue penetration of beta radiation allows for targeted destruction of malignant cells lining body cavities (pleural, peritoneal, or pericardial spaces), minimizing exposure to healthy tissues. Historically, it has also been used in radiosynovectomy for chronic synovitis but has largely been replaced by other isotopes in this indication[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphorus-32 colloid.